Back to Clinical Trials
Phase 1Starting soon

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

Sponsored by University of Chicago

About this study

The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer (NSCLC) receiving lorlatinib treatment will receive tirzepatide, a dual GIP/GLP-1 receptor agonist with demonstrated efficacy in weight reduction and metabolic improvement. This study seeks to evaluate its potential to mitigate side effects while preserving the therapeutic efficacy of lorlatinib.

Where this study is enrolling

  • University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois

    I'm interested
Who can participate

Inclusion criteria

  • ✓Age ≥ 18 years
  • ✓Receiving lorlatinib as first-line treatment for advanced NSCLC ALK-positive, already prescribed and administered by the patient's treating oncologist as standard of care at the time of study enrollment. This study does not initiate lorlatinib therapy or assign lorlatinib dosing; participants must already be receiving lorlatinib prior to enrollment

Exclusion criteria

  • ✕Known hypersensitivity to GLP-1 agonists.
  • ✕Active, unstable psychiatric illness; current suicidal ideation
  • ✕Severe organ dysfunction or systemic illness.
  • ✕Anorexia nervosa
  • ✕History of pancreatitis
  • ✕Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • ✕Current use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) or glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) \[GLP-1 RA/GIP\] co-agonist use within the last 90 days prior to screening
  • ✕Current anti-obesity medication use (other than GLP-1 RA) or dipeptidyl peptidase-4 (DPP4) inhibitor use or use within the last 30 days prior to screening
  • ✕Pregnant, breastfeeding or planning pregnancy

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.